2seventy bio Inc. When-Issued (TSVTV) Peer Comparison
$25.23
$2.34
(10.22%)
As on 06-Jan-2022EDT
Market cap
$621 Mln
Revenue (TTM)
$-- Mln
P/E Ratio
--
P/B Ratio
19.3
Div. Yield
0 %
Edit
| 2seventy bio Inc. When-Issued (TSVTV) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
621 | 14,631 | 12,066 | 12,237 | 10,826 |
Revenue ($ Mln) |
248 | 692 | 831 | 5,020 | 777 |
Net Profit ($ Mln) |
-120.11 | -696.24 | 54.90 | -199.00 | -191.64 |
Net Margin (%) |
-- | -100.64 | 6.61 | -3.96 | -24.68 |
RoE (%) |
-203.03 | -- | 8.11 | -3.03 | -223.36 |
Price to Earnings |
-- | -- | 248.04 | -- | -- |
Price-To-Book |
19.32 | 123.68 | 17.29 | 1.86 | 131.04 |
Income Statement ($ Mln)
| 2seventy bio Inc. When-Issued (TSVTV) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
248.12 | 8.25 | 353.87 | 3,273.30 | 0.00 |
|
Cost of Revenue
|
5.40 | 3.09 | 5.58 | 2,026.50 | 0.08 |
|
Gross Profit
|
242.73 | 8.25 | 348.29 | 1,246.80 | -0.08 |
|
Operating Expenses
|
392.76 | 482.73 | 220.09 | 1,323.60 | 99.14 |
|
Operating Profit (EBIT)
|
-144.64 | -474.48 | 128.20 | -76.80 | -99.14 |
|
Other Income
|
-- | 5.65 | 3.40 | 178.30 | -3.81 |
|
Profit before Tax
|
-120.11 | -505.49 | 131.60 | -672.00 | -102.90 |
|
Provision for Tax
|
-- | -21.56 | 25.59 | -111.90 | 2.49 |
|
Profit after Tax (Net Income)
|
-120.11 | -448.72 | 106.01 | -560.10 | -102.90 |
|
Minority Interest
|
-- | 48.35 | -- | -- | -- |
|
Consolidated Profit
|
-- | -448.72 | 106.01 | -560.10 | -102.90 |
Liabilities ($ Mln)
| 2seventy bio Inc. When-Issued (TSVTV) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
74.63 | 57.91 | 523.34 | 8,476.00 | 113.79 |
|
Minority Interest
|
-- | 48.35 | -- | -- | -- |
|
Non-Current Liabilities
|
162.12 | 500.05 | 37.84 | 7,140.00 | 48.90 |
|
Current Liabilities
|
75.87 | 95.65 | 10.55 | 2,077.00 | 23.44 |
|
Total Liabilities
|
312.62 | 703.59 | 571.73 | 17,693.00 | 186.13 |
Assets ($ Mln)
| 2seventy bio Inc. When-Issued (TSVTV) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
287.52 | 60.76 | 47.48 | 14,276.00 | 2.11 |
|
Current Assets
|
25.10 | 642.82 | 524.25 | 3,417.00 | 184.02 |
|
Total Assets
|
-- | 703.59 | 571.73 | 17,693.00 | 186.13 |
|
Total Debt*
|
-- | 495.79 | 2.55 | 6,127.00 | 50.12 |
|
Net Current Assets
|
-50.76 | 547.18 | 431.01 | 1,340.20 | 160.59 |
Cashflow ($ Mln)
| 2seventy bio Inc. When-Issued (TSVTV) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-67.79 | -399.71 | 151.97 | -41.00 | -78.46 |
|
Cash Flow from Investing Activities
|
-- | -52.99 | -119.26 | -4,779.20 | -0.05 |
|
Cash from Financing Activities
|
90.05 | 447.19 | 12.21 | 4,953.90 | 42.41 |
|
Net Cash Inflow / Outflow
|
-- | -5.52 | 44.92 | 133.70 | -36.09 |
Ratios
Profitability Ratios
| 2seventy bio Inc. When-Issued (TSVTV) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-203.03 | -85.15 | 23.54 | -4.98 | -56.76 |
|
ROE (%)
|
-203.03 | -192.44 | 23.70 | -7.99 | -70.36 |
|
ROA (%)
|
-38.28 | -67.21 | 21.55 | -4.20 | -50.60 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-48.41 | -3,228.69 | 29.67 | -16.23 | 2,698.78 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| 2seventy bio Inc. When-Issued (TSVTV) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
4.60 | -0.80 | 0.15 | 0.07 | -- |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
62.53 | -72.30 | 12.56 | -924.89 | -50.56 |
|
EPS Growth (%)
|
-- | -0.70 | 0.08 | -7.36 | -0.40 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| 2seventy bio Inc. When-Issued (TSVTV) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-- | -18.86 | 31.44 | -26.62 | -29.57 |
|
Price / Book Value
|
-- | 146.12 | 6.37 | 1.76 | 26.74 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-- | -17.87 | 19.12 | 22,826.39 | -29.00 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| 2seventy bio Inc. When-Issued (TSVTV) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-- | 8.56 | 0.00 | 0.72 | 0.44 |
|
Short term debt to equity ratio
|
-- | 0.09 | 0.00 | 0.07 | 0.01 |
|
Current Ratio
|
0.33 | 6.72 | 49.67 | 1.65 | 7.85 |
|
Quick Ratio
|
-- | -- | 47.67 | 0.89 | -- |
|
Interest Coverage
|
-- | -12.79 | 22.74 | -3.31 | -39.12 |
Operating Efficiency Ratios
| 2seventy bio Inc. When-Issued (TSVTV) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
4.31 | -- | 7.40 | 32.90 | -- |
|
Asset Turnover
|
0.79 | 0.01 | 0.72 | 0.25 | 0.00 |
|
Receivable days
|
13.33 | 125.97 | 23.80 | 109.74 | -- |
|
Inventory Days
|
-- | -- | 869.64 | 236.89 | -- |
|
Payable days
|
932.11 | 1,052.52 | 591.88 | 65.21 | 57,447.40 |
|
Cash Conversion Cycle
|
-- | -- | 301.57 | 281.42 | -- |
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
